Shots:
- Merus has entered into a global non-exclusive collaboration and license agreement with Halozyme Therapeutics to develop & commercialize SC formulation of petosemtamab using Halozyme’s Enhanze drug delivery technology
- As per the deal, Halozyme will receive an upfront, along with commercial & sales milestones payments, plus up to low-mid single-digit royalties; Although the financial details remain undisclosed
- Enhanze is a rHuPH20-based drug delivery technology that allows rapid SC administration of injected therapies & fluids to improve patient experience & reduce treatment burden
Ref: Merus| Image: Merus and Halozyme Therapeutics | Press Release
Related News:- Genmab to Acquire Merus for ~$8B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
